Form 4 Tracker
Benjamin Hohl

CHIEF FINANCIAL OFFICER · 6 filings · Latest: Sep 17, 2026

Enliven Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERSep 17, 2026
Sale
$50.356,018$303.0K38,000
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERSep 17, 2026
Option Exercise
$14.853,982$59.1K44,018
ELVN
Hohl Benjamin—Sep 17, 2026
Proposed Sale
$49.1212,036$591.2K—
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERAug 17, 2026
Sale
$58.586,018$352.6K40,036
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERJul 17, 2026
Sale
$52.646,018$316.8K46,054
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERJul 17, 2026
Option Exercise
$2.481,072$2.7K52,072
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERJun 17, 2026
Sale
$43.806,018$263.6K51,000
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERJun 17, 2026
Option Exercise
$2.486,018$14.9K57,018
ELVN
Hohl Benjamin—Jun 17, 2026
Proposed Sale
$42.5518,054$768.2K—
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERMar 6, 2026
Sale
$29.5810,000$295.8K51,000
ELVN
Hohl Benjamin—Mar 6, 2026
Proposed Sale
$29.2910,000$292.9K—
ELVN
Hohl Benjamin—Sep 29, 2025
Proposed Sale
$20.014,500$90.0K—
ELVN
Hohl Benjamin—Aug 27, 2025
Proposed Sale
$20.325,250$106.7K—
ELVN
Hohl Benjamin—Jul 28, 2025
Proposed Sale
$21.204,250$90.1K—
ELVN
Hohl Benjamin—Jun 27, 2025
Proposed Sale
$21.524,250$91.5K—
ELVN
Hohl Benjamin—Jun 13, 2025
Proposed Sale
$19.993,000$60.0K—
ELVN
Hohl Benjamin—May 27, 2025
Proposed Sale
$16.403,250$53.3K—
ELVN
Hohl Benjamin—Mar 27, 2025
Proposed Sale
$20.584,250$87.5K—
ELVN
Hohl Benjamin—Feb 27, 2025
Proposed Sale
$20.284,250$86.2K—
ELVN
Hohl Benjamin—Jan 27, 2025
Proposed Sale
$21.864,250$92.9K—

Page 1 of 2

Next →